Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: A study of 55 cases

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2669-2674

  Staněk, Libor ^a   Rozkoš, Tomáš ^b   Laco, Jan ^b   Ryška, Aleš ^b   Petruželka, Luboš ^a   Dura, Miroslav ^c   Dundr, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Gastric cancer; HER2; Immunohistochemistry; In situ hybridization; Quantitative polymerase chain reaction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME 17; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; INTESTINE CARCINOMA; MALE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; QUANTITATIVE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SILVER IN SITU HYBRIDIZATION; STOMACH BIOPSY; STOMACH CANCER; ADENOCARCINOMA; COMPARATIVE STUDY; GENETICS; LOWER ESOPHAGUS SPHINCTER; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84907210930     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2530     Document Type: Article

References (26)

1. Gravalos C and Jimeno A: HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
2. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
3. Pala EE, Bayol U, Ozguzer A and Akman O: HER2 status in gastric cancer: A comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest). Pathol Res Pract 209: 548-554, 2013.
4. Watson S, Validire P, Cervera P, et al: Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: A GERCOR study. Ann Oncol 24: 3035-3039, 2013.
5. Bang YJ: Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 46: 637-648, 2012.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
7. Daum O, Skálová A, Rozkos T and Laco J: Predictive diagnosis of HER2 in gastric adenocarcinoma. Cesk Patol 47: 160-163, 2011 (In Czech).
8. Ooi A, Kobayashi M, Mai M and Nakanishi I: Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest 78: 345-351, 1998.
9. Man YG, Moinfar F, Bratthauer GL, et al: An improved method for DNA extraction from paraffin sections. Pathol Res Pract 197: 635-642, 2001.
10. Jacquemier J, Spyratos F, Esterni B, et al: SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: A multicenter experience based on 840 cases. BMC Cancer 13: 351, 2013.
11. Fock KM: Review article: The epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 40: 250-260, 2014.
12. Sehdev A and Catenacci DV: Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med 16: 103-111, 2013.
13. Brien TP, Depowski PL, Sheehan CE, Ross JS and McKenna BJ: Prognostic factors in gastric cancer. Mod Pathol 11: 870-877, 1998.
14. Fox SB, Kumarasinghe MP, Armes JE, et al: Gastric HER2 Testing Study (GaTHER): An evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol 36: 577-582, 2012.
15. Hirschmann A, Lamb TA, Marchal G, Padilla M and Diebold J: Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas. Am J Clin Pathol 138: 837-844, 2012.
16. Cho EY, Srivastava A, Park K, et al: Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 44: 216-220, 2012.
17. Kiyose S, Igarashi H, Nagura K, et al: Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int 62: 728-734, 2012.
18. Lee S, de Boer WB, Fermoyle S, Platten M and Kumarasinghe MP: Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59: 832-840, 2011.
19. Takehana T, Kunitomo K, Kono K, et al: Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 98: 833-837, 2002.
20. Yano T, Doi T, Ohtsu A, et al: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15: 65-71, 2006.
21. Grin A, Brezden-Masley C, Bauer S and Streutker CJ: HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH. Appl Immunohistochem Mol Morphol 21: 561-566, 2013.
22. Yan B, Yau EX, Choo SN, et al: Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol 64: 880-883, 2011.
23. Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 40: 769-777, 2009.
24. García-García E, Gómez-Martin C, Angulo B, et al: Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: A comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology 59: 8-17, 2011.
25. Kim MA, Jung EJ, Lee HS, et al: Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum pathol 38: 1386-1393, 2007.
26. Tvrdík D, Staněk L, Skálová H, Dundr P, Velenská Z and Povysil C: Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Rep 6: 439-443, 2012.